Skip to main content
Platform trial launched by Multiple Myeloma Research Foundation

A new Phase I/II trial has been initiated by the Multiple Myeloma Research Foundation as an exclusive signal-finding study developed to establish MM molecular drivers that will test drugs such as cobimetinib, enasidenib, abemaciclib, erdafitinib, venetoclax and daratumumab in different MM subgroups. "Most of these drugs have already been tested in other cancers but we want to first see if it's hitting the target in multiple myeloma, then we'll move them into the combinations," said Kathy Giusti, MMRF founder and co-chair at the Harvard Business School Kraft Precision Medicine Accelerator.

Full Story: